Last update 06 Apr 2025

Aspirin

Overview

Basic Info

SummaryAspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, fever, and inflammation while also acting as an antithrombotic. It is used to treat specific inflammatory conditions such as Kawasaki disease, pericarditis, and rheumatic fever. Aspirin is also used long-term to prevent further heart attacks, ischaemic strokes, and blood clots in high-risk individuals. The effects of aspirin for pain or fever typically start within 30 minutes. Aspirin works similarly to other NSAIDs but also suppresses the normal functioning of platelets. Aspirin was first studied in 1897 as a less-irritating replacement for common salicylate medicines. By 1899, Bayer had named it "Aspirin" and sold it worldwide. Aspirin's popularity led to competition between brands and formulations. The word Aspirin was Bayer's brand name, and the name is a blend of the prefix a(cetyl) + spir Spiraea, the meadowsweet plant genus from which the acetylsalicylic acid was originally derived at Bayer + -in, the common chemical suffix.
Drug Type
Small molecule drug
Synonyms
Acetylsalicylic acid, ASA, Asiirin
+ [52]
Action
inhibitors, antagonists
Mechanism
COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors), TBXA2R antagonists(Thromboxane A2 receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (25 Jun 1965),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H8O4
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N
CAS Registry50-78-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Peripheral Arterial Disease
China
05 Sep 2022
Coronary Artery Disease
United States
04 Sep 2015
Ischemic Attack, Transient
United States
04 Sep 2015
Ischemic stroke
United States
04 Sep 2015
Mucocutaneous Lymph Node Syndrome
Japan
31 Oct 2005
Brain Ischemia
Japan
22 Sep 2000
Thrombosis
Japan
22 Sep 2000
Angina Pectoris
China
01 Jan 1998
Ankylosing Spondylitis
China
01 Jan 1998
Arthritis
China
01 Jan 1998
Gout
China
01 Jan 1998
Heart Valve Diseases
China
01 Jan 1998
Myocardial Infarction
China
01 Jan 1998
Fever
China
01 Jan 1981
Pain
China
01 Jan 1981
Migraine Disorders
United States
25 Jun 1965
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Atrial FibrillationPhase 3
France
25 May 2020
COVID-19Phase 3
Brazil
21 Apr 2020
COVID-19Phase 3
Canada
21 Apr 2020
COVID-19Phase 3
Colombia
21 Apr 2020
COVID-19Phase 3
Ecuador
21 Apr 2020
COVID-19Phase 3
Egypt
21 Apr 2020
COVID-19Phase 3
India
21 Apr 2020
COVID-19Phase 3
Nepal
21 Apr 2020
COVID-19Phase 3
Pakistan
21 Apr 2020
COVID-19Phase 3
Philippines
21 Apr 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
81
Rectal Biopsy+Aspirin
(Arm I (Aspirin))
ahfbakzzfq(jeukrejdtr) = gqglttjwuc etdkhkxqxh (lpbfebrmlr, wkvilnfyke - symanisxfy)
-
25 Mar 2025
Rectal Biopsy+Aspirin
(Arm II (Aspirin, Placebo))
ahfbakzzfq(jeukrejdtr) = rvtrshydit etdkhkxqxh (lpbfebrmlr, yhxcgkkcue - lplvkskhsh)
Phase 3
400
iljgizhcda = clqujctahl lcrofonhdp (nexbgxovxd, zahpbsxhtk - ojisjctwce)
-
25 Mar 2025
iljgizhcda = pijioeifti lcrofonhdp (nexbgxovxd, pphthocbwr - kzsjoqpdwm)
Phase 2
Sepsis | Shock, Septic
lactate | platelets | Pao2/Fio2 ratio
166
Acetylsalicylic Acid 200 mg
lzprlbdvhj(itsnjaqkks) = 8 [8.5%] vs. 1 [1.2%]; p = 0.02 vknamsudil (kfswczxinf )
Negative
01 Feb 2025
Placebo
Not Applicable
-
-
(Intervention Group (Alliteration Approach))
pbmntggpmz(iabdkqqmjy) = haurrghcps yoktuizjxo (jegsitnxop )
Positive
30 Jan 2025
(Control Group (Standard Approach))
pbmntggpmz(iabdkqqmjy) = hxhkurcdjy yoktuizjxo (jegsitnxop )
Phase 3
Colorectal Cancer
PIK3CA Mutation | PIK3R1 Mutation | PTEN Mutation ...
626
(PIK3CA mutations in exon 9 and/or 20)
femprsaann(xgjprvwtcp): HR = 0.49 (95% CI, 0.24 - 0.98), P-Value = 0.044
Positive
27 Jan 2025
Placebo
(PIK3CA mutations in exon 9 and/or 20)
Pubmed
ManualManual
Not Applicable
343,966
jstmtkywgx(lwhbgizyno) = ztjqjeezdh wknqioterq (kfxiuiytze )
Positive
02 Jan 2025
Not Applicable
-
-
(No BPA)
bcyleqkpse(iiucfjdtxa) = lokfzdrztn augdvfiwhu (banyssqldf )
-
07 Dec 2024
Phase 4
3,974
gpntimgiju(uxfcunthji): HR = 0.75 (95% CI, 0.53 - 1.04)
Positive
27 Nov 2024
Phase 2/3
60
Placebo
ppgdulsvhb(ryqbgqpgzt) = xyenniyikf yokhrcwlgu (itsrbsykgt, 1.537)
-
23 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free